What is the market doing?
What the tape says about RGC
Regencell Bioscience Holdings Limited is −49% over the past year while the S&P 500 is +20%: 69 points behind the market.
−49%
1-year return · S&P 500 +20%
- vs 200-day average
- −67%
vs 200-day average · a clear downtrend
- RSI (14)
- 79
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 87%
Below its 52-week high
Details›
- Last close2026-09-08
- $6.81
- 1 monthS&P 500 −0.30%
- +25%
- 1 yearS&P 500 +20%
- −49%
- 5 yearsS&P 500 +85%
- +2835%
- vs 50-day average$7.81
- −13%
- 52-week high
- $52.88
- 52-week low
- $4.75
- Annualised volatility
- 338%
| Year | Return |
|---|---|
| 2026 (year to date) | −68% |
| 2025 | +16054% |
| 2024 | −53% |
| 2023 | −62% |
| 2022 | −12% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | −3.1% |
| Feb | 5 | 3 of 5 | +2.2% |
| Mar | 5 | 1 of 5 | +102% |
| Apr | 5 | 5 of 5 | +26% |
| May | 5 | 2 of 5 | +270% |
| Jun | 5 | 2 of 5 | −20% |
| Jul | 5 | 1 of 5 | +24% |
| Aug | 6 | 2 of 6 | +39% |
| Sep | 6 | 3 of 6 | −5.7% |
| Oct | 5 | 3 of 5 | −3.1% |
| Nov | 5 | 2 of 5 | +6.7% |
| Dec | 5 | 2 of 5 | +15% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers - Specialty & Generic
Ranks #27 of 29 by Smart Score